We are building a native molecular intelligence platform to de-risk and accelerate preclinical drug development in an industry burdened by unsustainable failure rates, costs, and timelines.Our physics-grounded, modular, and data-efficient models can represent any molecular system and have already led to experimentally validated discoveries and accelerations across the preclinical value chain. By improving early-stage decision-making, we help shape better candidates from the start. We have signed LOIs and are negotiating potential contracts with leading biopharma, pursuing a dual-pronged go-to-market strategy: fee-for-service engagements and early-stage-partnerships. Backed by world-class advisors, we are focused on novel molecular formats with transformative therapeutic potential.
22.08.2025
DayOne Accelerator reveals latest cohort (startupticker.ch)
No milestones
No Jobs
No videos and documents
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Website:
www.lemna.bio/
Headquarter:
Villars-Tiercelin
Foundation Date:
August 2025
Technology:
Sectors: